主要文件

查看所有文档

O2881

盐酸奥昔布宁

Name: 盐酸奥昔布宁
Brand: SIGMA

≥98% (TLC), Muscarinic acetylcholine receptor antagonist, powder

别名:

α-苯基环己烷乙醇酸 4-(二乙基氨基)-2-丁炔酯盐酸盐

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₂H₃₁NO₃ · HCl

化学文摘社编号:

1508-65-2

分子量:

393.95

NACRES:

NA.77

PubChem Substance ID:

57654480

UNSPSC Code:

12352200

EC Number:

216-139-7

MDL number:

MFCD00072150

Assay:

≥98% (TLC)

Form:

powder

Quality level:

200

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

盐酸奥昔布宁, ≥98% (TLC), powder

Quality Level

200

assay

≥98% (TLC)

form

powder

color

white

solubility

H₂O: 50 mg/mL

originator

Johnson & Johnson

SMILES string

Cl.CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2

InChI

1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H

InChI key

SWIJYDAEGSIQPZ-UHFFFAOYSA-N

Gene Information

human ... CHRM1(1128), CHRM2(1129), CHRM3(1131), CHRM4(1132), CHRM5(1133)

说明

Biochem/physiol Actions

毒蕈碱型乙酰胆碱受体拮抗剂。

毒蕈碱型乙酰胆碱受体拮抗剂；可能通过下调生长促进基因，抑制膀胱平滑肌细胞的增殖。

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under 盐酸奥昔布宁

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin.

Naoki Aizawa et al.

European urology, 62(6), 1165-1173 (2012-09-18)

Mirabegron is the first β3-adrenoceptor agonist that is clinically effective for overactive bladder. The effects of mirabegron on primary bladder mechanosensitive single-unit afferent activities (SAAs) and bladder microcontractions were evaluated and compared with the effects of oxybutynin. Female Sprague-Dawley rats

Clinical effectiveness of early treatment with hyperbaric oxygen therapy for severe late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation in pediatric patients.

Daniele Zama et al.

Pediatric transplantation, 17(1), 86-91 (2012-12-13)

HC is a possible cause of morbidity and extended hospitalization after HSCT. Recent studies have reported the efficiency of HOT in adult patients who underwent allogeneic HSCT, but data in children are scarce. We report our single center experience with

P Tauzin-Fin et al.

Annales francaises d'anesthesie et de reanimation, 31(7-8), 605-608 (2012-07-04)

Catheter-related bladder discomfort (CRBD) is an unrecognized clinical event. Symptoms of CRBD secondary to an indwelling urinary catheter mimic those of an overactive bladder, i.e. urinary frequency and urgency with or without urge incontinence. Stimulation of muscarinic receptors located in

查看所有相关文献

全球贸易项目编号

货号	GTIN
O2881-1G	04061834227212
O2881-500MG	04061832092447
O2881-5G	04061832092454